Epigral gets CRISIL AA/Stable rating on ₹1,050 crore bank loans

Credit rating

Blacklitt Research29 October 20262 min read

A hand holding a pencil over papers near a laptop. — Photo by Scott Graham on Unsplash (Unsplash License). Illustrative image.

Epigral (NSE: EPIGRAL) has received revised ratings on its bank loan facilities from CRISIL Ratings, which assigned a long-term rating of CRISIL AA/Stable and a short-term rating of CRISIL A1+ to total facilities of ₹1,050 crore, it said in a filing on 29 Oct 2026.

Key highlights

Total bank loan facilities rated: ₹1,050 crore
Long-term rating: CRISIL AA/Stable
Short-term rating: CRISIL A1+
Rating letter dated 28 Oct 2026
Filed with the exchanges on 29 Oct 2026

The rating action in numbers

Item	Detail
Facilities rated	Total bank loan facilities of ₹1,050 crore
Long-term rating	CRISIL AA/Stable
Short-term rating	CRISIL A1+
Rating agency	CRISIL Ratings
Letter dated	28 Oct 2026
Action	Revised ratings assigned

What CRISIL assigned on the bank facilities

CRISIL Ratings assigned the revised ratings to Epigral in a letter dated 28 Oct 2026. The ratings cover total bank loan facilities of ₹1,050 crore, with a long-term rating of CRISIL AA/Stable and a short-term rating of CRISIL A1+.

The total amount rated is given, but the filing does not split the ₹1,050 crore across individual facilities.

Where the rating rationale is published

CRISIL published the rating rationale on its website, and the company gives the address of that page rather than the text. The rationale is the agency's own document, and the company's announcement carries only the ratings and the amount they cover.

What the revised ratings mean for Epigral's shareholders

The ratings and the amount they cover are stated, and the intimation is given for the information of shareholders and members. It does not say what the revision means for borrowing costs, results or the company's finances, or what the earlier ratings were.

The rating rationale on CRISIL's website is the agency's own account of the rating.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.